Recently, clinical trials have looked at patients who are attempting to stop TKI medications for a second time after relapsing during their first stopping attempt. These studies have shown that it is possible to stop a second time and be monitored for recurrence. The purpose of this study is to determine if adding ruxolitinib to a TKI prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission.
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
OPEN TO ACCRUAL